Advertisement

Topics

Non-Small Cell Lung Cancer Treatment Given Orphan Drug Designation

06:05 EDT 8 Aug 2017 | PharmPro

FDA grants orphan drug designation to Kadmon’s tesevatinib for the treatment of EGFR-mutated non-small cell lung cancer. It marks the second orphan drug designation for tesevatinib.
Contributed Author: 
Kadmon Holdings, Inc.
Topics: 

Original Article: Non-Small Cell Lung Cancer Treatment Given Orphan Drug Designation

NEXT ARTICLE

More From BioPortfolio on "Non-Small Cell Lung Cancer Treatment Given Orphan Drug Designation"

Quick Search
Advertisement
 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...